Ryan H. Flax
54 IP cases indexed. Covers patent matters.
Cases Presided Over
54 cases indexed | Page 2 of 2
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson Technology Limited successfully established a reasonable likelihood of prevailing in its IPR against Omachron Intellectual Property regarding vacuum cleaner technology. The Board found that combinations of prior art references rendered multiple claims obvious or anticipated.
Ilooda Co., Ltd. et al. v.Serendia, LLC
Endymed Medical and Serendia settled their inter partes review of U.S. Patent 9,480,836, leading the PTAB to terminate the proceeding under 35 U.S.C. § 317.
Jeisys Medical Inc. et al. v.Serendia, LLC
Serendia and Jeisys Medical settled their IPR dispute over U.S. Patent 9,320,536, leading the PTAB to terminate the proceeding.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef and Institute for Environmental Health settled four inter partes reviews covering patents 7,534,584; 8,822,143; 9,637,771; and 9,845,486. The Board terminated the proceedings based on a written settlement agreement and granted confidentiality for the agreement.
EndyMed Medical Ltd. et al. v.Serendia, LLC
EndyMed Medical and Serendia settled their inter partes review of U.S. Patent 9,480,836, leading the PTAB to terminate the proceeding. The settlement agreement is treated as confidential business information.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef Packing Company successfully challenged claims 1-30 of the '486 patent in a PTAB Institution Decision, establishing a reasonable likelihood that the methods for pathogen detection are unpatentable. The petitioner relied on prior art references including Rayman and Nagar to demonstrate anticipation and obviousness across multiple grounds.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their inter partes review disputes before the PTAB instituted the trial, resulting in termination of the proceedings and confidentiality of the settlement agreement.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef and Institute for Environmental Health settled four inter partes review proceedings, resulting in the termination of all petitions without a merits decision. The Board granted the joint motion to terminate and kept the settlement agreement confidential.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef Packing Company successfully petitioned to institute IPR against the '771 patent, establishing a reasonable likelihood of success over at least one claim. The Board adopted Petitioner's definition for 'validation,' clarifying that it merely requires a sample test negative, rejecting the Patent Owner's broader interpretation regarding commercial release.
Front Line Medical Technologies Inc. v.Prytime Medical Devices, Inc.
The PTAB institution decision found that the petitioner successfully demonstrated a likelihood of prevailing on its obviousness challenges against all ten claims. The Board adopted broad claim constructions for 'proximal hub' and 'flow valve,' finding they could be separate or sub-elements, which supported the grounds of obviousness over various prior art combinations.
Front Line Medical Technologies Inc. v.Prytime Medical Devices, Inc.
Petitioner successfully demonstrated that all ten challenged claims related to vascular occlusion catheters are unpatentable by a preponderance of the evidence. The Board relied heavily on various combinations of prior art references, primarily under 35 U.S.C. § 103 (obviousness).
Anker Innovations Limited v.Powermat Technologies Ltd.
The PTAB issued a Final Written Decision finding that claims 1–7 and 9–14 were unpatentable over prior art references. The petitioner successfully demonstrated obviousness under 35 U.S.C. § 103, particularly regarding the combination of Onishi and Flowerdew for independent claim 1.
NeoGenomics Laboratories, Inc. v.Natera, Inc.
NeoGenomics filed an IPR challenging Natera's prenatal‑testing patent. The parties settled before the Board could institute the trial, and the Board granted a joint motion to terminate the proceeding.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their dispute over U.S. Patent 10,327,607 B2, leading the PTAB to terminate the inter partes review by joint motion.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson successfully petitioned the PTAB to institute IPR proceedings against a patent covering cleaning apparatuses. The Board found reasonable likelihood of prevailing on grounds of anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103).
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
The PTAB denied Dyson's IPR challenge against Omachron's vacuum cleaner patent (10,568,477). The Board found that the Petitioner failed to demonstrate a reasonable likelihood of success, rejecting arguments based on prior art references like Brown and Dimbylow.
Cimbra SRL et al. v.3U Vision SRL
CIMBRIA SRL and 3U Vision settled their dispute over U.S. Patent 11,666,947, leading to a joint motion that terminated the post‑grant review. The Board granted the termination and ordered the settlement agreement to remain confidential.
Cimbra SRL et al. v.3U Vision SRL
Cimbra SRL challenged 3U Vision's optical sorting patent (11666947) on grounds of obviousness and indefiniteness, specifically over the prior art reference ElMasry. The PTAB preliminarily agreed that it is more likely than not that at least one claim would be unpatentable, instituting the proceeding for trial phase.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy’s and Eye Therapies settled their IPR dispute, resulting in a joint motion that terminated the proceedings. The Board granted the termination and kept the settlement confidential.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
The PTAB instituted the IPR petition challenging key claims of a patent related to vasoconstriction agents for eye redness. The Board found that Petitioner demonstrated a reasonable likelihood of prevailing, despite arguments from the Patent Owner regarding prior art limitations and adverse events.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom failed to convince the PTAB that Abbott's glucose monitoring patent was unpatentable based on obviousness grounds. The Board denied institution, finding insufficient evidence across multiple prior art combinations.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy’s Laboratories and Eye Therapies entered a settlement that led to the joint termination of two inter partes review proceedings covering patents 11,833,245 and 11,596,600. The Board granted the termination and kept the settlement agreement confidential.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy's Laboratories successfully secured institution status for an IPR against Eye Therapies, LLC regarding ophthalmic formulations. The Board found a reasonable likelihood of prevailing on obviousness (35 U.S.C. § 103) based on the combination of prior art references.
Ilooda Co., Ltd. et al. v.Serendia, LLC
EndyMed Medical and Serendia, LLC entered a settlement that resolved all disputes over three patents, leading the PTAB to terminate the associated IPRs. The settlement agreement was deemed confidential business information.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.